Haematological malignancies: at the forefront of immunotherapeutic innovation.
about
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromesImmunotherapy in Chronic Lymphocytic Leukaemia (CLL)Cellular immunotherapy as a beacon of hope for hematological malignancies'Trained immunity': consequences for lymphoid malignanciesGenomic and epigenomic heterogeneity in chronic lymphocytic leukemiaImmunotherapy in hematologic malignancies: past, present, and future.Rituximab-induced HMGB1 release is associated with inhibition of STAT3 activity in human diffuse large B-cell lymphoma.Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab eraMyeloid-derived suppressor cells in B cell malignancies.Anticancer potential of sanguinarine for various human malignancies.Recent advances in T-cell immunotherapy for haematological malignancies.Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.Antigen Loss Variants: Catching Hold of Escaping Foes.Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome.Phenotypic and clinical characterization of low density neutrophils in patients with advanced lung adenocarcinoma.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Specifically differentiated T cell subset promotes tumor immunity over fatal immunity.Towards personalized, tumour-specific, therapeutic vaccines for cancer.Myelodysplastic/myeloproliferative neoplasms: a disease in need of recognition.What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO).
P2860
Q26752940-3F526BEA-7DA9-4805-97F4-A6175A1F86A9Q26768154-BA898CB8-BC83-4415-8783-173D281F2F42Q26784288-136F8CEE-3E0C-44FE-956B-F9ECDDEE69D6Q28074639-01DAAC4B-2B57-454A-887C-C38E85FAC79CQ28087672-22663D5F-3CFA-4D59-A7FE-69B578A91C5CQ33593865-51C71255-A398-42BB-9AEF-593501DBF79BQ36413919-29C30FD2-4488-4A56-BF88-881FC8A14573Q37718312-E91034DF-B837-4F6B-8C20-3067DF44D671Q38578686-86A276B0-28EE-41CF-94FB-C43347A318E8Q38668494-8172E0BD-1BEB-47D5-9AD8-AB8FD74B201EQ38789518-61A00BE3-6E4C-4036-919B-6C23206F0F2DQ38822524-F69855CF-62D7-485B-91AC-3515AABC0535Q39175440-816AD505-4D58-4A26-9485-0DBE29F17F8EQ39243052-2CCC5B66-D231-4E7B-8E34-B0CB5DB28B9EQ40649778-6C6330BA-EA77-4EA6-BEA4-FB82007ADA3DQ47157214-48F78B8D-49DC-4CDA-BE1C-B612D90FB22AQ47447695-947965FF-F811-4AC5-BB92-A24C65BB93DBQ47643463-23215076-D64B-4614-9143-F42C966B7E42Q47789519-0ABB3A39-A0B9-4467-9A57-46129B13BA0AQ50891297-034B3821-2302-4CAD-8AC6-71DB70435527Q54839137-D0B21707-48CC-4483-BF83-BE3336969F2D
P2860
Haematological malignancies: at the forefront of immunotherapeutic innovation.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Haematological malignancies: at the forefront of immunotherapeutic innovation.
@ast
Haematological malignancies: at the forefront of immunotherapeutic innovation.
@en
type
label
Haematological malignancies: at the forefront of immunotherapeutic innovation.
@ast
Haematological malignancies: at the forefront of immunotherapeutic innovation.
@en
prefLabel
Haematological malignancies: at the forefront of immunotherapeutic innovation.
@ast
Haematological malignancies: at the forefront of immunotherapeutic innovation.
@en
P2093
P2860
P356
P1476
Haematological malignancies: at the forefront of immunotherapeutic innovation.
@en
P2093
Catherine J Wu
Mohini Rajasagi
Pavan Bachireddy
Ute E Burkhardt
P2860
P2888
P304
P356
10.1038/NRC3907
P407
P577
2015-03-19T00:00:00Z